Commentary on plateau in lupus nephritis trials and path to precision medicine
New lupus drugs hit a ceiling where kidney healing stops improving
This commentary reviews 200 interventional pharmacological trials in lupus nephritis. The authors note a persistent ceiling effect with comp…
Kidney healing in lupus patients using new drugs often stops improving after reaching a 40 to 50 percent success rate, limiting how much bet…
Narrative review highlights mechanistic gaps and limited efficacy in chronic inducible urticaria treatment options
New Hope for Chronic Hives Targets Specific Triggers
This narrative review examines chronic inducible urticaria (CIndU), focusing on H1-antihistamines, omalizumab, anti-KIT biologics, and BTK i…
New medicines are being built to fix the exact reason your hives appear, moving away from a one-size-fits-all approach.
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …